Delving into the Latest Updates on Basiliximab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Basiliximab (Genetical Recombination), Basiliximab (genetical recombination) (JAN), Basiliximab (USAN/INN)

+ [13]

Target

IL2RA

Action

inhibitors

Mechanism

IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors)

Therapeutic Areas

Immune System Diseases

Active Indication

Renal transplant rejectionGraft Rejection

Inactive Indication

Acute Graft Versus Host DiseaseAlpha 1-Antitrypsin DeficiencyBronchiolitis Obliterans+ [5]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Europharm Ltd.Novartis Pharma AGNovartis Pharma Schweiz AG

+ [1]

Inactive Organization

Novartis AG

Cerimon Pharmaceuticals, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 May 1998),

Graft Rejection

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 616716476H

Source: *****

Sequence Code 616716477L

Source: *****

This trial is to compare the risk/benefit profile over six-month follow-up of two induction immunosuppressive regimens based on one or seven low-dose perioperative RATG infusions on top of the same induction therapy with basiliximab and steroid (progressively tapered post-transplant) and maintenance therapy with calcineurin inhibitors and mycophenolate mofetil/mycophenolic acid in 75 recipients (25 Patients and 50 Reference-Patients) of a single or dual first kidney transplant from an ideal or marginal donor at a single Renal Transplant Center.

Start Date30 Jul 2024

Sponsor / Collaborator

Istituto di Ricerche Farmacologiche Mario Negri

NCT06480630

/ Not yet recruitingPhase 2IIT

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.

Start Date01 Jul 2024

Sponsor / Collaborator

Anhui Provincial Hospital

JPRN-UMIN000053362

/ RecruitingNot ApplicableIIT

Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations - Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations

Start Date01 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Basiliximab

Login to view more data

100 Translational Medicine associated with Basiliximab

Login to view more data

100 Patents (Medical) associated with Basiliximab

Login to view more data

1,779

Literatures (Medical) associated with Basiliximab

01 Nov 2025·FOOD CHEMISTRY

Gel properties, phase behavior and flavor of double-network surimi gel: Interactions, performance and mechanisms

Article

Author: Zhou, Ruizi ; Chen, Lei ; Bai, Shuxian ; Lan, Haijing ; Teng, Hui ; Ai, Chao

This study systematically investigated the synergistic effects of chitosan (CHI) and transglutaminase (TG) on improving the gel properties, structural characteristics, textural quality and flavor profile of surimi products. The results showed that through the synergistic effects of non-covalent and covalent interactions, CHI and TG successfully constructed a stable dual-network gel system, which increased the water holding capacity and gel strength were increased by 67.34 % and 71.98 % respectively. 1 % CHI +0.4 % TG formulation effectively restricted water mobility and increased the proportion of immobilized water to 97.97 %. The content of β-sheet increased to 68 % and the microstructure became more compact and ordered, with a decrease in porosity of 44.49 %. Furthermore, the dual-network gel system demonstrated simultaneous improvements in both textural and flavor characteristics. These findings provide novel insights into the development of advanced surimi products with dual-network structures, highlighting the technological advantages of CHI-TG combination over conventional single-network systems.

01 Nov 2025·PEDIATRIC TRANSPLANTATION

ABO Incompatible Kidney Transplantation in Indian Children

Article

Author: Bansal, Virinder ; Krishna, Asuri ; Sinha, Aditi ; Bagga, Arvind ; Yadav, Menka ; Coshic, Poonam ; Hari, Pankaj ; Goswami, Sanjeev ; Singh, Geetika ; Meena, Jitendra

ABSTRACT:

Background:

Kidney transplantation programs in developing countries chiefly depends on live donors, and waiting lists are long for patients lacking ABO compatible (ABOc) donors. ABO incompatible (ABOi) transplantation enhances the donor pool. We report our experience of ABOi kidney transplantation in children.

Methods:

We screened medical records of ABOi and ABOc kidney transplantation performed at this center between January 2019 to December 2023. For desensitization of ABOi kidney allograft recipients a combination of rituximab and either immunoadsorption or plasma exchange along with IVIg was used. Induction regimen comprised either basiliximab or ATG, followed by maintenance therapy with tacrolimus, mycophenolate mofetil and prednisolone. We retrieved data on recipient and donor characteristics, immunosuppression, and post‐transplant complications. Allograft and patient survival were estimated using Kaplan–Meier survival analysis.

Results:

During the 5‐years, 7 ABOi and 46 ABOc kidney transplantation were performed. The mean follow up duration was 24.9 ± 17.1 months in ABOi group and 30.3 ± 18.8 months in ABOc group. Patient age, native kidney disease, donor profile and other characteristics were comparable. Rejection free graft survival was similar between ABOi and ABOc groups (p = 0.88). Median (IQR) eGFR at last follow up was 61.4 (46.6, 74.3) ml/min/1.73 m2 in ABOi group and 50.9 (39.7, 68.9) ml/min/1.73 m2 in ABOc group (p = 0.23). Patients and graft survival rates were similar in both groups.

Conclusions:

Our findings suggest that ABOi kidney transplantation in children in India is feasible and associated with satisfactory outcomes P.

01 Oct 2025·CLINICAL TRANSPLANTATION

Early Removal of Ureteral Stents When Attached to the Foley Catheter in Living Donor Kidney Transplant Recipients Reduces Urinary Tract Infections

Article

Author: Kesik, Esma ; Bunn, Weslyn ; Prieto, Mikel ; Bentall, Andrew ; Smith, Byron ; Nyberg, Scott ; Stegall, Mark D. ; Rebolledo, Patricia ; Schinstock, Carrie ; Ovdat, Esther ; Perry, Dana ; Elali, Ibrahim ; Mahgoub, Mohammed ; Mao, Shennen ; Jadlowiec, Carrie ; Reddy, Kunam ; Lam, Jenny

ABSTRACT:

Background:

Ureteral stents are commonly placed during kidney transplantation (KT) to mitigate urologic complications. The objective of this study was to compare clinical outcomes in KT recipients with either early stent removal when attached to the Foley catheter or late removal via cystoscopy when unattached.

Methods:

We conducted a multi‐center retrospective analysis of consecutive living donor KT patients (8/18/21‐4/21/23) stratified into Foley‐attached and unattached stent groups. Outcomes assessed were ureteral stricture, urine leaks, UTIs at 90 days and allograft failure and BKV DNAemia (BK virus DNAemia) at 1 year. Data are reported as mean and standard deviation.

Results:

Among 247 patients with attached and 260 with unattached stents, baseline demographics (age, sex, diabetes) were similar between groups. There was a difference in race (87.9% vs. 77.8% Caucasian; p = 0.004). Foley catheters remained longer in the attached group (3.7 ± 1.8 vs. 3.0 ± 2.0 days; p < 0.001), but stents were removed earlier (3.7 ± 1.8 vs. 21.9 ± 4.7 days; p < 0.001). Comparing attached versus unattached, there were no differences in ureteral stricture (0.4% vs. 1.5%; p = 0.197), urine leak (0.8% vs. 0.4%; p = 0.533), BKV DNAemia (17.7% vs. 16.9%; p = 0.616), or allograft failure (0% vs. 0.8%; p = 0.167). However, UTI incidence by 90 days was lower in the attached group (5.7% vs. 11.9% p = 0.013). Induction therapy differed significantly between groups, with Alemtuzumab more common in the unattached group (58.1% vs. 19.4%, p < 0.001), Basiliximab more common in the attached group (43.3% vs. 35.0%, p < 0.001), and Thymoglobulin more common in the attached group (36.0% vs. 6.9%, p < 0.001). Baseline steroid use was higher in the unattached group (81.9% vs. 57.9%, p < 0.001).

Conclusion:

Early stent removal via connection to the Foley catheter had similarly low rates of ureteral complications while reducing urinary tract infections and avoiding cystoscopic removal.

100 Deals associated with Basiliximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03058	Basiliximab	L04AC02	DB00074

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Renal transplant rejection	European Union	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	Iceland	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	Liechtenstein	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	Norway	Novartis Europharm Ltd.	09 Oct 1998
Graft Rejection	United States	Novartis Pharmaceuticals Corp.	12 May 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Phase 3	United States	Novartis AG	01 May 2009
Alpha 1-Antitrypsin Deficiency	Phase 3	Canada	Novartis AG	01 May 2004
Bronchiolitis Obliterans	Phase 3	Canada	Novartis AG	01 May 2004
Pulmonary Emphysema	Phase 3	Canada	Novartis AG	01 May 2004
Hepatitis C	Phase 3	-	Novartis AG	01 Dec 2002
Non-infectious posterior uveitis	Phase 2	United States	Cerimon Pharmaceuticals, Inc.	01 May 2008
Colitis, Ulcerative	Phase 2	United States	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Phase 2	Belgium	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Phase 2	Czechia	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Phase 2	India	Cerimon Pharmaceuticals, Inc.	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2024 Manual	Not Applicable	Refractory Acute Graft Versus Host Disease	92	Basiliximab	ywyljsgpep(rgzhyyqgeb) = pckbmujrgo nflrmtcllu (qargedhyik ) View more	Positive	01 Feb 2024
NCT02464878 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	2	Islet Transplantation+Thymoglobulin+Basiliximab+Alpha 1-Antitrypsin+Etanercept	kifvecqwhf = vzwbehriso dqiijlfbvi (ttcbflqerk, lcbsncdaeh - njyogqioun) View more	-	22 Dec 2023
ASH2023	Not Applicable	Steroid Refractory Graft Versus Host Disease	60	Basiliximab and Infliximab	fdfzkddzut(bdrgqmyqlk) = nrtjbonyhf okdepsfacd (fkvoqexdyk ) View more	-	11 Dec 2023
EHA2023	Not Applicable	Chronic graft-versus-host disease Second line	20	Basiliximab treatment	pbtnxogkyw(bozuzdflww) = cwntspnufb yjadzoasrn (sqmvdqtjkb ) View more	-	08 Jun 2023
EHA2023	Not Applicable	Chronic graft-versus-host disease Second line	20	BASILIXIMAB (Control group)	pbtnxogkyw(bozuzdflww) = ggrfdgczjt yjadzoasrn (sqmvdqtjkb ) View more	-	08 Jun 2023
NCT02123108 (CTgov)	Phase 4	-	59	Basiliximab+Tacrolimus+Mycophenolic Acid (Basiliximab)	ltulokowcz = emkidveioo npneyzoidt (zvkpkjxjln, xmmvuupbrp - oafuesytcg) View more	-	29 Sep 2022
NCT02123108 (CTgov)	Phase 4	-	59	Tacrolimus+Mycophenolic Acid (Tacrolimus Group)	ltulokowcz = fpkmtfwxrr npneyzoidt (zvkpkjxjln, ksdsardxex - kkulamxukw) View more	-	29 Sep 2022
NCT02366728 (ELEVATE, CTgov)	Phase 2	Glioblastoma Multiforme \| Tetanus	64	111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed+autologous DCs+Saline (Group I: Unpulsed DC Pre-conditioning)	tsvpphrkwf(cmzuolyphu) = tweppamyws carxusmkui (aiwoxltnxa, sukwqhjhby - avykkurdic) View more	-	01 Feb 2022
NCT02366728 (ELEVATE, CTgov)	Phase 2	Glioblastoma Multiforme \| Tetanus	64	111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed+autologous DCs+Saline (Group II: Tetanus Pre-conditioning)	tsvpphrkwf(cmzuolyphu) = scwxfgbvpf carxusmkui (aiwoxltnxa, iuchbkwriv - sahzmwnptp) View more	-	01 Feb 2022
NCT00679042 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	21	Islets of Langerhan+Simulect+Rapamune+Prograf+Byetta+Enbrel	qzttdikuwu = eyreshldup pdrununbgf (lgybgtxflq, rlwaerxali - zdsmsehatq) View more	-	06 Apr 2021
P054 (EBMT2021)	Not Applicable	Steroid Refractory Graft Versus Host Disease	-	Basiliximab	rlsgdzglii(fpniljioal) = gnivvmadua dypxgibvla (qqyktcydgd ) View more	Positive	14 Mar 2021
P1775 (ERA2020)	Not Applicable	Cytomegalovirus viremia	-	Basiliximab induction	gqimzpnhox(stbtsmjzrl) = mkclldpuos ujgofkxvnn (pumtzyoeqo ) View more	Positive	06 Jun 2020
P1775 (ERA2020)	Not Applicable	Cytomegalovirus viremia	-	Low-dose ATG induction	gqimzpnhox(stbtsmjzrl) = gbwxyaohho ujgofkxvnn (pumtzyoeqo ) View more	Positive	06 Jun 2020
EHA2020	Not Applicable	Steroid Refractory Graft Versus Host Disease	230	Basiliximab	remkmztydw(qdwcttalcn) = Patient receiving more than 4 doses of basiliximab treatment were associated with a higher risk of infection nvgdlrhxjn (fyiiklcozu )	Positive	14 May 2020

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data